Castle Biosciences (CSTL) Depreciation and Depletion (2018 - 2026)

Castle Biosciences has reported Depreciation and Depletion for 9 years, with the latest figure at $1.8 million in Q2 2026.

• Quarterly Depreciation and Depletion rose 25.19% year-over-year to $1.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $6.6 million (up 17.43% YoY) and the FY2025 annual result came in at $5.9 million, up 21.3% from the prior year.
• Depreciation and Depletion improved to $1.8 million in Q2 2026 per CSTL's latest filing, from $1.7 million in the prior quarter.
• Over five years, Depreciation and Depletion peaked at $1.8 million in Q2 2026 and troughed at $503000.0 in Q1 2022.
• A 5-year average of $1.1 million and a median of $1.1 million in 2024 frame the typical range for Depreciation and Depletion.
• The sharpest annual moves came in 2022 and 2025: Depreciation and Depletion jumped 115.88% in 2022, then grew 5.11% in 2025.
• Over 5 years, Depreciation and Depletion stood at $627000.0 in 2022, then jumped by 51.99% to $953000.0 in 2023, then surged by 49.84% to $1.4 million in 2024, then rose by 5.11% to $1.5 million in 2025, then rose by 21.19% to $1.8 million in 2026.
• According to Business Quant data, Depreciation and Depletion over the past three periods registered $1.8 million, $1.7 million, and $1.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.